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Abstract
Background: Malignant granular cell tumor (MGCT) is a rare disease entity. Forty-one well-
documented MGCTs have been reported in the world literature.
Case Report: This report describes a patient who presented with a MGCT of the lung and
reviews the preoperative evaluation, pathologic features and differential diagnosis of the disease.
This case represents the first report of resected primary pulmonary MGCT.
Conclusions:  Diagnosis of MGCT is based on histology of the primary tumor,
immunohistochemistry, and exclusion of tumors that may mimic granular cell tumor.
Introduction
Granular cell tumors (GCT) are uncommon, usually
benign neoplasms, most frequently originating from
tongue, skin, and breast [1,2]. Since the first case of GCT
from the trachea and bronchus was described in the late
1930s, less than 80 cases have been reported as originat-
ing from in the tracheobronchial tree, all of which were
benign. One report suggested a MGCT co-existing with
small cell lung cancer; however, no histology proof was
available since the tumor was not resected [3]. In this
report, we describe a patient who presented with a MGCT
of the lung and discuss the preoperative considerations
and evaluation, differential diagnosis, and the pathologic
features of this rare malignancy.
Case Report
A 32-year-old Caucasian woman who was in her usual
state of health until approximately 2 months ago was
admitted for her new onset of chest pain and shortness of
breath. She had a longstanding history of smoking since
the age of 9, roughly 2–3 packs per day. Physical examina-
tion was within normal limits; no evidence of peripheral
adenopathy or cutaneous nodules was noted. A chest x-
ray and CT scan revealed a solitary pulmonary mass (Fig.
1, 2). The mass was round and smooth, 2.8 cm in diame-
ter, and centrally located within the left lower lobe.
Additional work-up including abdominal and pelvic CT
scans revealed no extra-pulmonary lesions. Because of her
significant smoking history, clinical symptoms and imag-
ing studies, a tentative preoperative diagnosis of lung can-
cer was made. A flexible bronchoscopy was then
performed, which revealed no evidence of endobronchial
lesions. Subsequently, a lateral thoracotomy was per-
formed. In-situ, the centrally located mass was smooth by
palpation and was in close proximity to the pulmonary
hilum. There were no visible invasive or metastatic lesions
in the adjacent organs or lymph nodes. Four core biopsies
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were taken from the mass, but no definite pathologic diag-
nosis of tumor was made on intraoperative frozen section.
A diagnostic lobectomy was subsequently performed. The
patient had an uneventful postoperative course and was
discharged from hospital 4 days postoperatively.
Macroscopically, the tumor was a well-defined solitary
mass, measuring 2.8 × 2.0 × 2.0 cm in size. It was located
at 2.2 cm from the bronchial margin of resection and 1.5
cm from the over-lining pleural surface. The cut surface of
the tumor had a whitish tan appearance and firm consist-
ency. The mass was well-circumscribed but not encapsu-
lated, and did not infiltrate the bronchial wall. The
surrounding pulmonary parenchyma had a slightly con-
gested appearance. Six lymph nodes were identified in the
peri-bronchial region, the largest measured 1.1 cm in
diameter.
Microscopically, the mass was intimately associated with
a segmental bronchus and had grown circumferentially
along the submucosal and muscular wall. The mass was
made of sheets of granular cells. The neoplastic cells dis-
played moderate atypia, with a marked increase in cellu-
larity and nuclear/cytoplasm (N:C) ratio, greater
pleomorphism, nucleolar prominence, identifiable
mitotic figures, and prominent spindling of tumor cells
(Fig. 3). The cytoplasmic granules were PAS-positive and
resistant to diastase digestion. Immunohistochemical
staining for S-100 protein revealed prominent cytoplasm
reaction products in the tumor cells. Staining for vimentin
was weakly positive. Tumor cells exhibited increased
expression of both p53 and Ki67, with more than 4% and
25% of tumor cells positive for Ki-67 and p53, respec-
tively. The tumor cells did not stain for carcinoembryonic
antigen, cytokeratins, epithelial membrane antigen, actin,
desmin, myoglobin, smooth muscle actin, CD34, or
HMB-45. All six lymph nodes were negative for tumor
metastases. The lesion was pathologically diagnosed as a
MGCT based on the morphologic findings, results of an
immunohistochemical panel, increased p53 expression,
and an elevated nuclear proliferative index.
Discussion
MGCT is a rare disease entity that was first described by
Ravich et al, in 1945 [4]. Since the originally described
case, forty-one additional MGCTs have been reported in
various body sites, including skin, oral cavity, breast,
abdominal wall, chest wall and urinary bladder [5,6]. Dif-
ferentiation between benign and malignant GCTs is often
difficult, since only the presence of metastasis may ulti-
mately establish malignancy. Because MGCTs are
extremely rare, attempts have been made to identify spe-
cific histologic features that would predict malignant
behavior. Based on the cumulative experience of previous
case reports of MGCTs, six histologic criteria are consid-
ered to be important [1,7]. These malignant features
included spindling of the tumor cells, the presence of
vesicular nuclei with large nucleoli, increased mitotic rate
(>2 mitoses/10 high-power fields at 200× magnification),
a high nuclear-to cytoplasm (N:C) ratio, pleomorphism,
and necrosis [7]. Histologically, MGCT is diagnosed when
three or more of the six criteria are fulfilled. In addition to
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the histologic features, upregulation of p53 as well as
Ki67, a nuclear proliferative marker, has been recently
found to correlate with an aggressive clinical course and
malignant behavior. In a recent study, p53 immunostains
were negative in all benign cases [7], while p53 expression
was seen in greater than 10% of the cell population in 21
of 25 (79%) MGCTs. Similarly, benign GCTs showed
immunoreactivity of Ki-67 in 1 % or less of the tumor cell
population, while fourteen of 25(56%) malignant tumors
had Ki67 immunopositivity in up to 30% of the cell pop-
ulation. Our case fulfilled five of the six histologic features
of malignant GCT.
Increased expression of p53 and an elevated Ki-67 expres-
sion in the tumor cells further supported the diagnosis. In
addition, malignant tumors that may mimic MGCT were
excluded based on histologic and immunophenotypic
features. These excluded neoplasms are alveolar soft part
sarcoma, rhabdomyosarcoma, leiomyoma, leiomyosar-
coma, angiosarcoma, malignant fibrous histocytoma,
melanoma and malignant peripheral nerve sheath tumor
(MPNST). Furthermore, the possibility of a metastatic
malignant GCT originating from an extrapulmonary site
was excluded by the thorough preoperative evaluation.
Metastatic malignant GCT to the lung usually presents
with bilateral nodules rather than a single solitary mass.
MGCT is more commonly seen in women with a female
to male ratio being 2.4:1. Patient age at presentation
ranges from 23 to 82 years with the average age at diagno-
sis being 48 years. The more common benign counterpart
has been described in all age groups, including newborns.
Therefore, age of the patient is not a particularly helpful
factor when attempting to distinguish benign from malig-
nant form of the disease. Size of MGCTs ranges from 0.5
cm to 17 cm and approximately half of these are 4 cm or
larger at the time of diagnosis. The size of the primary
lesion alone is not a reliable predictor of the malignant
behavior because many of the MGCT were less than 4 cm.
The options for treatment of GCT of the lung are based on
tumor size. Small tumors (<1.0 cm) may be treated by
bronchoscopic extirpation, laser therapy, or sleeve resec-
tion. Larger tumors (>1.0 cm) that usually extend beyond
the tracheobronchial cartilage are usually treated by surgi-
cal resection [4]. However, no uniform management of
malignant GCT is yet available, since this is the first docu-
mented pulmonary malignant GCT.
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Microscopically, the tumor was made of sheets of granular 
cells with moderate atypia, prominent spindling, increased 
nuclear/cytoplasm ratio and greater pleomorphism. Note 
two giant tumor cells were in the central field of the photo-
graph. (Hematoxylin and eosin; × 400)